- Home
- AUPH vs ATAI Comparison
AUPH vs ATAI Comparison
Compare AUPH & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | ATAI |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AUPH | ATAI |
|---|---|---|
| Price | $15.20 | $3.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $17.25 | $14.33 |
| AVG Volume (30 Days) | 1.1M | ★ 3.2M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $265,808,000.00 | $3,018,000.00 |
| Revenue This Year | $21.76 | $943.18 |
| Revenue Next Year | $16.45 | N/A |
| P/E Ratio | $28.99 | ★ N/A |
| Revenue Growth | 20.62 | ★ 811.78 |
| 52 Week Low | $6.55 | $1.15 |
| 52 Week High | $16.54 | $6.75 |
Technical Indicators
Market Signals| Indicator | AUPH | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 40.97 |
| Support Level | $15.64 | $3.90 |
| Resistance Level | $15.98 | $4.72 |
| Average True Range (ATR) | 0.39 | 0.26 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 13.73 | 10.64 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.